Richard N. Kender
Chairman
Seres Therapeutics, Inc. (MCRB)Board Member
Seres Therapeutics, Inc. (MCRB)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Richard N. Kender
Richard N. Kender is recorded as CEO, Chairman and Board Member at Seres Therapeutics, Inc. (MCRB). Seres Therapeutics, Inc. reported in an 8-K filed July 8, 2026 that Richard N. Kender was appointed Class II director, effective July 8, 2026. Seres Therapeutics, Inc. reported in an 8-K filed March 2, 2026 that Richard N. Kender was appointed Executive Chair of the Board, effective March 2, 2026. Seres Therapeutics, Inc. reported in an 8-K filed March 2, 2026 that Richard N. Kender was appointed Interim Chief Executive Officer, effective March 2, 2026.
“Based on the foregoing votes, the director nominees listed in Item 1 were elected and Items 2 through 5 were approved.”
“On February 27, 2026, the Board of Directors (the "Board") of Seres Therapeutics, Inc. (the "Company") appointed Richard N. Kender, a current member of the Board, to serve as Executive Chair of the Board and as Interim Chief Executive Officer of the Company, Matthew Henn, Ph.D., the Company's Chief Scientific Officer, to the additional role of President, and Kelly Brady, M.S., the Company's Senior Vice President, Clinical Development, to the role of Executive Vice President, Chief Operating Officer, each effective March 2, 2026 (the "Effective Date").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-03-02–present
-
Current
2014-01-01–present
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Seres Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Marella Thorell CEO, CFO, Chief Accounting Officer
- Roger J. Pomerantz CEO
- Kelly Brady COO
- Kelly Brady, M.S. COO
- David S. Ege CTO
- David Arkowitz Chief Accounting Officer
- Eric Shaff Chief Accounting Officer
- Claire Fraser, Ph.D. Board Member
- Claire M. Fraser, Ph.D. Board Member
- Dennis A. Ausiello Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.